NovaScan offers MarginScan™, a compact device that uses high‑frequency spectral bioimpedance and AI/ML to provide real‑time, non‑destructive cancer margin assessment during surgery. The system delivers specific electrical signatures of malignant tissue within seconds, enabling surgeons to preserve healthy tissue, reduce re‑operations, and streamline workflow without requiring dedicated pathology resources.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Surgeons lack rapid, intraoperative tools to assess cancer margins, often relying on frozen sections or postoperative pathology that are time‑consuming, resource‑intensive, and can lead to unnecessary removal of healthy tissue or repeat surgeries.
Solution
NovaScan’s MarginScan™ device provides real‑time, non‑destructive cancer margin assessment by combining high‑frequency spectral bioimpedance with AI/ML analysis. The system measures the Cole relaxation frequency, which differs by orders of magnitude between malignant and benign cells, delivering a highly specific electrical signature of cancer. Results are generated within seconds, allowing surgeons to make immediate decisions about tissue removal without needing dedicated pathology staff or frozen‑section equipment. The technology preserves the specimen for standard histopathology if desired and integrates seamlessly into existing surgical workflows for skin, breast, and other oncologic procedures. By enabling healthier tissue‑sparing surgery, MarginScan™ aims to improve clinical outcomes, reduce re‑operation rates, and lower procedural costs.
Target Audience
Primary customers are surgical teams performing oncologic resections—particularly Mohs surgeons, breast‑conserving surgeons, and hospital pathology departments seeking rapid intraoperative margin assessment.
Features
- Compact, stand‑alone device that performs spectral bioimpedance measurements at clinically relevant frequencies
- AI‑driven algorithms interpret Cole relaxation frequency data to detect and localize residual cancer with 85‑100% specificity
- Instantaneous, non‑destructive readout delivered in seconds, eliminating the need for frozen sectioning
- Compatible with standard histopathology workflows, allowing post‑operative tissue analysis if required
- Designed for integration into skin cancer Mohs‑type procedures and breast‑conserving surgeries, supporting healthy‑tissue sparing
- Manufactured by PHC Group with exclusive U.S. distribution through Epredia